• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ISAR-REACT 5 - What have we learned?

作者信息

Kubica Jacek, Jaguszewski Miłosz

机构信息

Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.

First Department of Cardiology, Medical University of Gdansk, Poland.

出版信息

Cardiol J. 2019;26(5):427-428. doi: 10.5603/CJ.a2019.0090. Epub 2019 Sep 19.

DOI:10.5603/CJ.a2019.0090
PMID:31536136
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8084390/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3568/8084390/007edbeaa6a5/cardj-26-5-427f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3568/8084390/007edbeaa6a5/cardj-26-5-427f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3568/8084390/007edbeaa6a5/cardj-26-5-427f1.jpg

相似文献

1
ISAR-REACT 5 - What have we learned?ISAR-REACT 5研究——我们学到了什么？
Cardiol J. 2019;26(5):427-428. doi: 10.5603/CJ.a2019.0090. Epub 2019 Sep 19.
2
Prasugrel vs. ticagrelor after acute coronary syndrome: a critical appraisal of the ISAR-REACT 5 trial.急性冠脉综合征后普拉格雷与替格瑞洛的比较：对ISAR-REACT 5试验的批判性评估
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):273-274. doi: 10.1093/ehjcvp/pvz077.
3
[The ISAR-REACT 5 trial: is there a winner between prasugrel and ticagrelor in acute coronary syndromes?].[ISAR-REACT 5试验：在急性冠状动脉综合征中，普拉格雷和替格瑞洛谁更胜一筹？]
G Ital Cardiol (Rome). 2020 Mar;21(3):171-174. doi: 10.1714/3306.32764.
4
Ticagrelor or Prasugrel in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.替格瑞洛或普拉格雷在接受直接经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者中的应用。
Circulation. 2020 Dec 15;142(24):2329-2337. doi: 10.1161/CIRCULATIONAHA.120.050244. Epub 2020 Oct 29.
5
Ticagrelor monotherapy in patients with diabetes mellitus undergoing percutaneous coronary interventions: insights from the TWILIGHT trial.替格瑞洛单药治疗糖尿病患者经皮冠状动脉介入治疗：来自TWILIGHT试验的见解。
Cardiovasc Res. 2020 Jun 1;116(7):e70-e72. doi: 10.1093/cvr/cvaa120.
6
Reloading When Switching From Ticagrelor or Prasugrel to Clopidogrel Within 7 Days After STEMI.ST段抬高型心肌梗死（STEMI）后7天内从替格瑞洛或普拉格雷转换为氯吡格雷时的重新负荷用药
JACC Cardiovasc Interv. 2020 Mar 9;13(5):663-665. doi: 10.1016/j.jcin.2020.01.001.
7
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.替格瑞洛或普拉格雷在急性冠状动脉综合征患者中的应用。
N Engl J Med. 2019 Oct 17;381(16):1524-1534. doi: 10.1056/NEJMoa1908973. Epub 2019 Sep 1.
8
Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.替格瑞洛或普拉格雷与氯吡格雷三联抗血小板治疗联合糖蛋白 IIb/IIIa 抑制剂用于接受 PCI 的 STEMI 患者：一项荟萃分析。
BMC Cardiovasc Disord. 2020 Mar 12;20(1):130. doi: 10.1186/s12872-020-01403-6.
9
Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.替格瑞洛与氯吡格雷在经皮冠状动脉介入治疗中携带两个 CYP2C19 失活等位基因的患者中的比较。
Cardiovasc Drugs Ther. 2020 Apr;34(2):179-188. doi: 10.1007/s10557-020-06956-4.
10
Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016.2009 - 2016年普拉格雷和替格瑞洛在经皮冠状动脉介入治疗后稳定性缺血性心脏病中的应用
Circ Cardiovasc Interv. 2019 Jan;12(1):e007434. doi: 10.1161/CIRCINTERVENTIONS.118.007434.

引用本文的文献

1
Pretreatment with P2Y Receptor Inhibitors in Acute Coronary Syndromes-Is the Current Standpoint of ESC Experts Sufficiently Supported?急性冠状动脉综合征中P2Y受体抑制剂的预处理——欧洲心脏病学会专家的当前观点是否有充分依据？
J Clin Med. 2023 Mar 19;12(6):2374. doi: 10.3390/jcm12062374.
2
Pre-hospital treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams. Expert position update 2022.急性冠状动脉综合征患者的院前治疗：医疗急救团队的建议。2022年专家立场更新
Cardiol J. 2022;29(4):540-552. doi: 10.5603/CJ.a2022.0026. Epub 2022 May 6.
3
Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor.

本文引用的文献

1
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.替格瑞洛或普拉格雷在急性冠状动脉综合征患者中的应用。
N Engl J Med. 2019 Oct 17;381(16):1524-1534. doi: 10.1056/NEJMoa1908973. Epub 2019 Sep 1.
2
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).2017年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的冠状动脉疾病双联抗血小板治疗重点更新：欧洲心脏病学会（ESC）和欧洲心胸外科学会（EACTS）冠状动脉疾病双联抗血小板治疗特别工作组。
Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419.
3
普拉格雷和替格瑞洛治疗的心肌梗死患者血小板聚集的昼夜变化
J Clin Med. 2022 Feb 21;11(4):1124. doi: 10.3390/jcm11041124.
4
Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines.急性冠状动脉综合征患者的长期抗血栓治疗：对现行欧洲心脏病学会指南的批判性评价。
Cardiol J. 2020;27(6):661-676. doi: 10.5603/CJ.a2020.0132. Epub 2020 Oct 19.
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).2017年欧洲心脏病学会（ESC）ST段抬高型急性心肌梗死患者管理指南：欧洲心脏病学会（ESC）ST段抬高型急性心肌梗死患者管理工作组
Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393.
4
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).2015年欧洲心脏病学会（ESC）非持续性ST段抬高型急性冠脉综合征患者管理指南：欧洲心脏病学会（ESC）非持续性ST段抬高型急性冠脉综合征患者管理工作组
Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29.
5
Discrepancies in assessment of adherence to antiplatelet treatment after myocardial infarction.心肌梗死后抗血小板治疗依从性评估中的差异。
Pharmacology. 2015;95(1-2):50-8. doi: 10.1159/000371392. Epub 2015 Jan 15.
6
Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis.基于 MEMS 与自我报告问卷测量的药物依从性率的相关性：一项荟萃分析。
Health Qual Life Outcomes. 2010 Sep 13;8:99. doi: 10.1186/1477-7525-8-99.